BACKGROUND: Multisite trials, the gold standard for conducting studies in community-based settings, can mask variability across sites resulting in misrepresentation of effects in specific sites. In a placebo-controlled trial of osmotic-release oral system methylphenidate (OROS-MPH) as augmentation treatment for smokers with attention deficit hyperactivity/impulsivity disorder (ADHD), three types of sites were selected according to their clinical research specialty (ADHD, smoking cessation, and general mental health). OBJECTIVE: Analysis was conducted to determine if clinical outcomes, that is, reduction in ADHD symptoms and smoking cessation rates, and the effect of treatment on these outcomes would differ by type of site. METHOD: A total of 255 adult smokers diagnosed with ADHD were enrolled in three clinic types: 72 in ADHD, 79 in tobacco dependence, and 104 in the mental health clinics. RESULTS: The three site-types were similar in demographic characteristics, smoking history, baseline level of ADHD symptoms, and history of psychiatric illness. Site-type but not a site-type by treatment interaction predicted prolonged smoking abstinence. A significant three-way interaction of site-type, treatment, and time-predicted improvement in ADHD symptoms. Moderate to strong effects of OROS-MPH relative to placebo were observed in the mental health and the ADHD clinics; a weak effect was observed in the tobacco dependence clinics. CONCLUSION: OROS-MPH benefit varied by site for reducing ADHD symptoms but not for improving smoking abstinence. SCIENTIFIC SIGNIFICANCE: Assessment of site-type effects can indicate the generalizability of findings from multisite trials and should be routinely incorporated in the design of multisite trials.
RCT Entities:
BACKGROUND: Multisite trials, the gold standard for conducting studies in community-based settings, can mask variability across sites resulting in misrepresentation of effects in specific sites. In a placebo-controlled trial of osmotic-release oral system methylphenidate (OROS-MPH) as augmentation treatment for smokers with attention deficit hyperactivity/impulsivity disorder (ADHD), three types of sites were selected according to their clinical research specialty (ADHD, smoking cessation, and general mental health). OBJECTIVE: Analysis was conducted to determine if clinical outcomes, that is, reduction in ADHD symptoms and smoking cessation rates, and the effect of treatment on these outcomes would differ by type of site. METHOD: A total of 255 adult smokers diagnosed with ADHD were enrolled in three clinic types: 72 in ADHD, 79 in tobacco dependence, and 104 in the mental health clinics. RESULTS: The three site-types were similar in demographic characteristics, smoking history, baseline level of ADHD symptoms, and history of psychiatric illness. Site-type but not a site-type by treatment interaction predicted prolonged smoking abstinence. A significant three-way interaction of site-type, treatment, and time-predicted improvement in ADHD symptoms. Moderate to strong effects of OROS-MPH relative to placebo were observed in the mental health and the ADHD clinics; a weak effect was observed in the tobacco dependence clinics. CONCLUSION:OROS-MPH benefit varied by site for reducing ADHD symptoms but not for improving smoking abstinence. SCIENTIFIC SIGNIFICANCE: Assessment of site-type effects can indicate the generalizability of findings from multisite trials and should be routinely incorporated in the design of multisite trials.
Authors: John March; Helena C Kraemer; Madhukar Trivedi; John Csernansky; John Davis; Terence A Ketter; Ira D Glick Journal: Neuropsychopharmacology Date: 2010-08-25 Impact factor: 7.853
Authors: Edward V Nunes; Samuel Ball; Robert Booth; Gregory Brigham; Donald A Calsyn; Kathleen Carroll; Daniel J Feaster; Denise Hien; Robert L Hubbard; Walter Ling; Nancy M Petry; John Rotrosen; Jeffrey Selzer; Maxine Stitzer; Susan Tross; Paul Wakim; Theresa Winhusen; George Woody Journal: J Subst Abuse Treat Date: 2010-06
Authors: Lenard A Adler; Thomas Spencer; Stephen V Faraone; Fred W Reimherr; Douglas Kelsey; David Michelson; Joseph Biederman Journal: J Atten Disord Date: 2005-02 Impact factor: 3.256
Authors: Eric T Moolchan; Aleksandras Radzius; David H Epstein; George Uhl; David A Gorelick; Jean Lud Cadet; Jack E Henningfield Journal: Addict Behav Date: 2002 Jan-Feb Impact factor: 3.913
Authors: John R Hughes; Josue P Keely; Ray S Niaura; Deborah J Ossip-Klein; Robyn L Richmond; Gary E Swan Journal: Nicotine Tob Res Date: 2003-02 Impact factor: 4.244
Authors: Theresa M Winhusen; Eugene C Somoza; Gregory S Brigham; David S Liu; Carla A Green; Lirio S Covey; Ivana T Croghan; Lenard A Adler; Roger D Weiss; Jeffrey D Leimberger; Daniel F Lewis; Emily M Dorer Journal: J Clin Psychiatry Date: 2010-05-18 Impact factor: 4.384
Authors: Ivana T Croghan; Judith A Trautman; Theresa Winhusen; Jon O Ebbert; Frankie B Kropp; Darrell R Schroeder; Richard D Hurt Journal: Contemp Clin Trials Date: 2012-03-03 Impact factor: 2.226
Authors: Arthur N Westover; T Michael Kashner; Theresa M Winhusen; Richard M Golden; Paul A Nakonezny; Bryon Adinoff; Steven S Henley Journal: Am J Drug Alcohol Abuse Date: 2015-06-11 Impact factor: 3.829
Authors: Karolina Kozak; Aliya M Lucatch; Darby J E Lowe; Iris M Balodis; James MacKillop; Tony P George Journal: Ann N Y Acad Sci Date: 2018-10-05 Impact factor: 5.691